BP Asset IX

BP Asset IX is a subsidiary of Boston Pharmaceuticals. The company's Efimosfermin is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog therapy in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), including cirrhosis, as well as future developments in alcohol-related liver disease (ALD), two forms of SLD. Currently, treatment options for MASH and ALD are limited, and they are the leading causes of liver transplantation in the United States, representing a significant burden and cost to healthcare.